OGN - Organon Q2 2022 Earnings Preview

• Organon ( NYSE: OGN ) is scheduled to announce Q2 earnings results on Thursday, August 4th, before market open.
• The consensus EPS Estimate is $1.19 (-30.8% Y/Y) and the consensus Revenue Estimate is $1.53B (-3.8% Y/Y).
• Over the last 1 year, OGN has beaten EPS estimates 100% of the time and has beaten revenue estimates 100% of the time.
• Over the last 3 months, EPS estimates have seen 0 upward revisions and 7 downward. Revenue estimates have seen 1 upward revision and 5 downward.
• In Q1, Organon, the Merck ( MRK ) spinoff focused on women’s health and biosimilars, reported better than expected financials thanks to the outperformance of its established brands segment.
• Women’s Health brought $378M, indicating a ~5% YoY decline, and revenue from Biosimilars rose ~22% YoY to $99M.
• For 2022, Organon projects $6.1B - $6.4B revenue vs 6.18B consensus.
• Recent earnings Analysis from our contributors: Organon: Some Uncomfortable Questions Ahead Of Q2 Earnings

For further details see: